Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo
Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase its laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo in Chicago. The company will unveil next-generation core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience how Roche's integrated systems and data solutions optimize resources and streamline operations.
Key innovations include the future cobas® Mass Spec solution, new CCM Vertical, cobas® liat system for rapid PCR testing, cobas® pure integrated solutions, cobas® eplex system, cobas® 5800, and cobas® LightCycler® PRO. Roche will also present its navify® digital solutions and host Roche Idea Lab sessions featuring industry experts discussing topics such as mass spectrometry, digital solutions, and respiratory testing.
Roche (SIX: RO, ROG; OTCQX: RHHBY) presenterà la sua laboratorio del futuro all'Associazione per la Diagnostica e la Medicina di Laboratorio (ADLM) durante il Meeting Scientifico e l'Expo Clinica a Chicago nel 2024. L'azienda svelerà sistemi di laboratorio e molecolari di nuova generazione, inclusa una soluzione completa per la spettrometria di massa clinica. I partecipanti potranno vedere come i sistemi integrati e le soluzioni dati di Roche ottimizzano le risorse e semplificano le operazioni.
Le innovazioni chiave includono la futura soluzione cobas® Mass Spec, il nuovo CCM Vertical, il sistema cobas® liat per test PCR rapidi, le soluzioni integrate cobas® pure, il sistema cobas® eplex, il cobas® 5800 e il cobas® LightCycler® PRO. Roche presenterà anche le sue soluzioni digitali navify® e ospiterà sessioni del Roche Idea Lab con esperti del settore che discuteranno argomenti come la spettrometria di massa, le soluzioni digitali e i test respiratori.
Roche (SIX: RO, ROG; OTCQX: RHHBY) mostrará su laboratorio del futuro en la Reunión Científica y la Expo de Laboratorio Clínico de la Asociación para Diagnósticos y Medicina de Laboratorio (ADLM) en Chicago en 2024. La compañía presentará sistemas de laboratorio y moleculares de próxima generación, incluida una solución total para la espectrometría de masas clínica. Los asistentes podrán experimentar cómo los sistemas integrados y las soluciones de datos de Roche optimizan recursos y agilizan operaciones.
Las innovaciones clave incluyen la futura solución cobas® Mass Spec, el nuevo CCM Vertical, el sistema cobas® liat para pruebas PCR rápidas, las soluciones integradas cobas® pure, el sistema cobas® eplex, el cobas® 5800 y el cobas® LightCycler® PRO. Roche también presentará sus soluciones digitales navify® y organizará sesiones del Roche Idea Lab con expertos de la industria tratando temas como espectrometría de masas, soluciones digitales y pruebas respiratorias.
로슈(Roche) (SIX: RO, ROG; OTCQX: RHHBY)는 2024년 시카고에서 열리는 진단 및 의학 실험실 협회(ADLM) 과학 회의 및 임상 실험실 엑스포에서 미래의 실험실 전시회를 선보일 예정입니다. 이 회사는 임상 질량 분석을 위한 총 솔루션을 포함한 차세대 핵심 실험실 및 분자 시스템을 공개할 것입니다. 참석자들은 로슈의 통합 시스템과 데이터 솔루션이 자원을 최적화하고 운영을 간소화하는 방법을 경험할 수 있습니다.
주요 혁신 사항으로는 미래의 코바스(cobas®) 질량 분석 솔루션, 새로운 CCM 수직 시스템, 신속 PCR 테스트를 위한 코바스(cobas®) 리앗 시스템, 코바스(cobas®) 퓨어 통합 솔루션, 코바스(cobas®) 이플렉스 시스템, 코바스(cobas®) 5800 및 코바스(cobas®) 라이트사이클러(LightCycler®) PRO가 포함됩니다. 로슈는 또한 나비파이(navify®) 디지털 솔루션을 소개하고 산업 전문가들이 질량 분석, 디지털 솔루션 및 호흡기 검사와 같은 주제를 논의하는 로슈 아이디어 랩 세션을 개최할 것입니다.
Roche (SIX: RO, ROG; OTCQX: RHHBY) présentera son laboratoire du futur lors de la réunion scientifique et de l'expo clinique de l'Association pour le Diagnostic et la Médecine de Laboratoire (ADLM) à Chicago en 2024. L'entreprise dévoilera des systèmes de laboratoire et moléculaires de nouvelle génération, y compris une solution complète pour la spectrométrie de masse clinique. Les participants pourront découvrir comment les systèmes intégrés et les solutions de données de Roche optimisent les ressources et rationalisent les opérations.
Les innovations clés incluent la future solution cobas® Mass Spec, le nouveau CCM Vertical, le système cobas® liat pour les tests PCR rapides, les solutions intégrées cobas® pure, le système cobas® eplex, le cobas® 5800, et le cobas® LightCycler® PRO. Roche présentera également ses solutions numériques navify® et animera des sessions Roche Idea Lab avec des experts du secteur abordant des sujets tels que la spectrométrie de masse, les solutions numériques et les tests respiratoires.
Roche (SIX: RO, ROG; OTCQX: RHHBY) wird sein Lab der Zukunft auf dem wissenschaftlichen Treffen und der klinischen Laborexpo der Vereinigung für Diagnostik und Laboratoriumsmedizin (ADLM) in Chicago im Jahr 2024 präsentieren. Das Unternehmen wird Systeme für zentrale Labore und molekulare Analysen der nächsten Generation vorstellen, einschließlich einer Gesamtlösung für die klinische Massenspektrometrie. Die Teilnehmer können erleben, wie die integrierten Systeme und Datenslösungen von Roche Ressourcen optimieren und Abläufe rationalisieren.
Zu den wichtigen Innovationen gehören die zukünftige cobas® Mass Spec-Lösung, das neue CCM Vertical, das cobas® liat-System für schnelle PCR-Tests, cobas® pure integrierte Lösungen, das cobas® eplex-System, cobas® 5800 und cobas® LightCycler® PRO. Roche wird auch seine navify® digitalen Lösungen präsentieren und Roche-Idea-Lab-Sitzungen leiten, in denen Branchenexperten über Themen wie Massenspektrometrie, digitale Lösungen und Atemwegstests diskutieren.
- Unveiling next-generation core lab and molecular systems
- Showcasing integrated systems and data solutions to optimize resources and streamline operations
- Introducing the future cobas® Mass Spec solution for clinical mass spectrometry
- Expanding the cobas® liat system menu to include testing for four common respiratory viruses
- Presenting navify® digital solutions for secure data integration across care settings
- None.
- Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry.
- Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operations, optimize resources and expedite care.
- The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how elevating diagnostics can lead to more insights and better patient outcomes.
"Laboratorians strive to deliver trusted, timely test results to patients with greater effectiveness and efficiency. Our latest generation of cobas® solutions are proven to deliver seamless integration of systems and data to support these efforts," said Brad Moore, president and CEO of Roche Diagnostics North America. "We are excited to share these next-generation solutions, which are the building blocks for future laboratories, and are eager to partner with our customers so that they can both do more with less and deliver the best possible outcomes for patients."
Focusing on key attributes of science-based leadership, operational simplicity and patient-centric partnership, Roche will feature its newest innovations in-booth at ADLM, including:
- The future cobas® Mass Spec solution*, is designed to be a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory.
- The new CCM Vertical is a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas® connection modules.
- The cobas® liat system brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing menu of assays, now including the cobas liat SAR-CoV-2, Influenza A/B & RSV assay** to test for four common respiratory viruses, all within one test.
- The cobas® pure integrated solutions combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs.
- The cobas® eplex system, a rapid syndromic molecular diagnostic solution, has been updated with new features across all aspects of the workflow process.
- The cobas® 5800 is a compact, fully automated molecular PCR-testing solution with a comprehensive menu of assays.
- The cobas® LightCycler® PRO is a qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories with an improved user experience.
Roche also will present its full array of navify® digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Our digital solutions enable confident healthcare decisions and help you drive operational, clinical and financial value.
With the largest diagnostics installed base worldwide, Roche provides unrivaled ability to scale access to testing at speed for those who need it most. The cobas® reagent portfolio offers the broadest menu on an integrated platform and includes the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays, aiming to more effectively detect and support an Alzheimer's diagnosis.
Roche will also present eight Roche Idea Lab segments in booth 2003, where experts will discuss topics such as mass spectrometry, digital solutions, respiratory testing, and the use of high-medical-value assays when treating Alzheimer's and heart failure. Scientific industry workshops will include "Laboratorians' Perspectives on Evaluation and Implementation of Alzheimer's CSF Assays" and "Making a Subjective Sepsis Diagnosis More Objective: The Role of AI-based Sepsis Medical Algorithms in Empowering Healthcare Decisions." For more information about Roche's participation at ADLM 2024 and Roche Idea Lab programming, visit ADLM.roche.com.
Featured Roche Idea Lab sessions include:
Tuesday, July 30
Improving Access and Patient Outcomes for Sexually Transmitted Infections | 11 a.m. CST
This session will delve into innovative strategies for enhancing patient access to STI testing and shed light on the promising potential of these approaches to positively impact public health outcomes.
Barbara Van Der Pol, Ph.D., MPH, University of
Moving Beyond the Transactional Operation with navify® Digital Solutions to Unlock New Possibilities for Better Care | 2:30 p.m. CST
This session will explore how navify® cutting-edge algorithms help move beyond transactional operations to foster a holistic approach for better care with AI.
Peter McCaffrey, M.D., University of
Testing for Heart Failure in People with Diabetes – What Do the New ADA Guidelines Mean for Labs? | 3:30 p.m. CST
This session will discuss how to put the American Diabetes Association recommendation for heart failure risk monitoring in all people with diabetes into practice.
Ibrahim A. Hashim, M.Sc., Ph.D., C.Sci., FIBMS, DABCC, FAACC, UT Southwestern Medical Center, Parkland Hospital and Health System
Wednesday, July 31
Advancing Respiratory Testing Across the Continuum of Care | 10:30 a.m. CST
This session will discuss how strategies to improve diagnostic stewardship for respiratory infections contribute to better patient care.
David Gaston, M.D., Ph.D., and Alisha Ezell, MHA, MLS(ASCP)CM, Vanderbilt Health
Making Patient Impact with Ions: A Conversation on the Medical Value of Mass Spectrometry | 1 p.m. CST
This session will feature a conversation on the medical value of mass spectrometry and provide specific case examples related to patient outcomes.
Victoria Zhang, Ph.D., MBA, DABCC, University of Rochester Medical Center
The Pathway to Growing Your Lab | 2:30 p.m. CST
This session will share ideas on how labs can remain competitive by utilizing existing capacity and improving access for patients in support of optimized clinical care.
Steve Serota and Robin Herbner, Wisconsin Diagnostic Laboratories
Are You Listening? The Black Pregnant Woman's Instincts and Preeclampsia | 3:30 p.m. CST
This session will discuss the Black woman's experience with healthcare and the role diagnostics can play in improving outcomes for preeclampsia patients.
Sarosh Rana, M.D., MPH, FACOG, University of Chicago Medicine
Current and Future Biomarker Testing Landscape in Alzheimer's Disease | 4:15 p.m. CST
This session will discuss how the availability of Alzheimer's biomarkers in CSF and blood is revolutionizing the diagnostic path.
Leslie Shaw, Ph.D., University of
*Not currently for sale in
**This product has not been cleared or approved by the Food and Drug Administration (FDA), but has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories.
About Roche
Founded in 1896 in
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For Further Information:
To find more information on Roche and images for media use, please visit the Roche Media Library.
Roche Diagnostics
us.mediarelations@roche.com
Onsite at ADLM:
Gina Goodenough
+1-317-734-7171
gina.goodenough@roche.com
Multimedia assets
cobas® Mass Spec solution image
CCM Vertical image
cobas® liat system image
cobas® pure integrated solutions image
cobas® eplex system image
cobas® 5800 image
cobas® LightCycler® PRO image
View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-showcases-solutions-for-laboratories-of-the-future-at-the-association-for-diagnostics--laboratory-medicine-2024-clinical-lab-expo-302206616.html
SOURCE Roche Diagnostics
FAQ
What new products will Roche (ROG) showcase at the ADLM 2024 Clinical Lab Expo?
How does Roche (ROG) aim to improve laboratory operations with its new solutions?
What topics will be covered in Roche's (ROG) Idea Lab sessions at ADLM 2024?
What is the cobas® liat system by Roche (ROG) and what are its capabilities?
